natgillin/translations-raw huggingface dataset:
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 
Kõrvaltoimete esinemissagedus on defineeritud järgnevalt: - väga sage (ühe ravikuuri jooksul ilmnes(id) kõrvaltoime(d) rohkem kui 1-l loomal 10 looma hulgast) - sage (rohkem kui 1-l, kuid vähem kui 10 loomal 100-st) - aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st) - harv (rohkem kui 1-l, kuid vähem kui 10 loomal 10,000-st) - väga harv (vähem kui 1-l loomal 10,000-st, kaasaarvatud harva esinevad üksikjuhud).
Pregnancy: This vaccine is specifically indicated during pregnancy. 
Tiinus: See vaktsiin on näidustatud kasutamiseks spetsiaalselt tiinuse perioodil.
No undesirable effects other than those mentioned in the “Adverse reactions” section have been observed after the administration of several doses. 
Pärast mitmete dooside manustamist pole täheldatud teisi kõrvaltoimeid kui need, mis on ära toodud punktis “ Kõrvaltoimed”
Dogs (pregnant bitches) 
Koer (tiine emaskoer)
The reconstituted content shall be a milky emulsion. 
Lahustatud vaktsiin peab olema piimjas emulsioon.
10 doses: powder (10 bottles) + solvent (10 bottles) 50 doses: powder (50 bottles) + solvent (50 bottles) 
1 doos: pulber (1 pudel) + lahusti (1 pudel) 10 doosi: pilber (10 pudelit) + lahusti (10 pudelit) 50 doosi: pulber (50 pudelit) + lahusti (50 pudelit)
This vaccine is specifically indicated during pregnancy. 
See vaktsiin on spetsiaalselt näidustatud kasutamiseks tiinuse perioodil.
Overdose: 
Üledoseerimine:
Special precautions to be taken by the person administrating the veterinary medicinal product to animals: 
Ettevaatusabinõud veterinaarravimit loomale manustavale isikule:
Light paraffin oil ......................................................................................................... 224.8 to 244.1 mg For the full list of excipients, see section 6.1. 
Kerge parafiinõli ..................................................................................................... 224.8 kuni 244.1 mg Abiainete terviklik loetelu on esitatud punktis 6.1.
Purified subunit vaccine for the active immunisation of pregnant bitches to induce passive immunity in puppies against herpesvirus-induced fatal neonatal disease. 
Puhastatud alamühikuline vaktsiin tiinete emaskoerte aktiivseks immuniseerimiseks, et kutsuda esile passiivne immuunsus kutsikatel herpesviiruse põhjustatud surmlõppega neonataalse haiguse vastu.
Eurican Herpes 205 solvent 
Eurican Herpes 205 lahusti
Manufacturer responsible for batch release: MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, 69800 Saint Priest, France 
Laboratoire Porte des Alpes Rue de l'Aviation, 69800 Saint Priest, Prantsusmaa
Polyoxyethylene fatty acids Ether of fatty alcohols and of polyols Triethanolamine 
Polüoksüetüleen rasvhapped Rasvalkoholide ja polüoolide eeter Trietanoolamiin
Box of 2 x 1 bottle, 2 x 10 bottles and 2 x 50 bottles. 
Karbis 2 x 1 pudel, 2 x 10 pudelit ja 2 x 50 pudelit.
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life through passive immunity. 
Emaskoerte aktiivne immuniseerimine, et vältida koerte herpesviirusinfektsioonist põhjustatud surma, kliiniliste tunnuste ning kahjustuste tekkimist kutsikatel esimestel elupäevadel passiivse immuunsuse kaudu.
Light paraffin oil 
Kerge parafiinõli
The vaccine may commonly cause transient oedema at the site of injection. 
Vaktsiin võib tavaliselt põhjustada mööduvat turset süstekohal.
Abortion and premature parturition can occur as a result of CHV infection in bitches, the protection of the bitch against infection has not been studied for this vaccine. 
Emaste koerte kaitsmist nakkuse vastu ei ole selle vaktsiini jaoks uuritud.
Incompatibilities: 
Sobimatus:
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Active substance: 
TOIMEAINE(D) JA MUUD ABIAINE(D) Toimeaine:
Shelf life after reconstitution: use immediately 
Kõlblikkusaeg pärast lahustamist: Kasutada koheselt pärast lahustamist.
Name and address of the manufacturer of the biological active substance(s) 
Bioloogilis(t)e toimeaine(te) tootja nimi) ja aadress
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. 
Kui oled juhuslikult endale ravimit süstinud, võtta kaasa pakendi infoleht ja pöörduda kiiresti arsti poole, isegi kui süstitud kogus oli väga väike.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJAJA TOOTMISLOA HOIDJAKES VASTUTAB RAVIMIPARTII VÄLJASTAMISE EEST
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND 
A. BIOLOOGILISTE TOIMEAINETE TOOTJA(D) JA RAVIMIPARTII
Once reconstituted use immediately. 
Peale lahustamist kasutada koheselt.
Aseptically reconstitute the contents of the powder with the solvent supplied with this vaccine. 
Vaktsiinipulber tuleb aseptiliselt lahustada kaasas oleva lahustiga.
Subcutaneous use. 
Nahaaluseks süstimiseks.
Powder and solvent for emulsion for injection. 
Pulber ja lahusti süsteemulsiooni valmistamiseks.
Eurican Herpes 205 powder for injection 
Eurican Herpes 205 pulber süsteemulsiooni valmistamiseks
Do not mix with any other veterinary medicinal product except the solvent supplied for use with the veterinary medicinal product. 
Seda ravimpreparaati ei tohi segada teiste vaktsiinidega või immunoloogiliste preparaatidega välja arvatud kaasas olev lahusti.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Box of 2 x 1 bottle, 2 x 10 bottles and 2 x 50 bottles 
Karbis 2 x 1 pudel, 2 x 10 pudelit ja 2 x 50 pudelit
PACKAGE LEAFLET FOR: Eurican Herpes 205 powder and solvent for emulsion for injection 
PAKENDI INFOLEHT Eurican Herpes 205 pulber ja lahusti süsteemulsiooni valmistamiseks
Name and address of the manufacturer responsible for batch release 
Ravimipartii väljastamise eest vastutavatootja nimi ja aadress MERIAL
ROUTE(S) OF ADMINISTRATION 
Rue de l'Aviation
Powder and solvent for emulsion for injection Lyophilisate : white pellet. 
Lüofilisaat: valge pellet Lahusti: homogeenne valge emulsioon
Eurican Herpes 205 powder and solvent for emulsion for injection 
Eurican Herpes 205 pulber ja lahusti süsteemulsiooni valmistamiseks
The European Commission granted a marketing authorisation valid throughout the European Union for Enviage to Novartis Europharm Limited on 22 August 2007. 
Euroopa Komisjon andis Enviage müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Novartis Europharm Limited 22. augustil 2007.
‘Essential' means that the hypertension has no obvious cause. 
„Essentsiaalne” tähendab, et hüpertensioonil ei ole selget põhjust.
The medicine's effects were maintained for up to a year in two of the studies. 
Ravimi toime püsis kahes uuringus kuni aasta jooksul.
Enviage is not recommended for use in patients below 18 years of age, because of a lack of information on safety and effectiveness in this age group. 
Enviaget ei soovitata kasutada alla 18 aasta vanustel patsientidel, sest ohutuse ja efektiivsuse andmed selle vanuserühma kohta puuduvad.
The Committee recommended that Enviage be given marketing authorisation. 
Komitee soovitas anda Enviagele müügiloa.
It is available as tablets (pink and round: 150 mg; red and oval: 300 mg). 
Seda turustatakse tablettidena (roosad ümmargused: 150 mg; punased ovaalsed: 300 mg).
Enviage was studied in 14 main studies involving over 10,000 patients with essential hypertension. 
Enviage kasutamist uuriti 14 põhiuuringus, milles osales rohkem kui 10 000 essentsiaalse hüpertensiooniga patsienti.
The studies also showed that Enviage, when taken in combination with other medicines (especially hydrochlorothiazide), can produce additional decreases in blood pressure compared with the decreases produced by these medicines when they are taken without Enviage. 
Uuringud näitasid ka, et Enviage kasutamisel koos teiste ravimitega (eriti hüdroklorotiasiidiga) võib vererõhk väheneda enamgi, võrreldes vähenemisega nende ravimite kasutamisel ilma Enviageta.
The recommended dose of Enviage is 150 mg once a day, either taken alone or in combination with other medicines for hypertension. 
Enviage soovituslik annus on 150 mg üks kord päevas kas ainsa ravimina või koos teiste kõrgvererõhuravimitega.
When the results of the five studies comparing Enviage taken alone with placebo were looked at together, patients aged under 65 years had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Enviage, from an average of 99.4 mmHg at the start of the study. 
Viie uuringu kokkuvõttes, milles võrreldi Enviage kasutamist ainsa ravimina platseebo kasutamisega, vähenes alla 65 aasta vanuste patsientide diastoolne vererõhk pärast 150 mg Enviage kasutamist kaheksa nädala jooksul keskmiselt 9,0 mm Hg võrra, võrreldes keskmise rõhuga 99,4 mm Hg ravi algul.
This may reduce the risks associated with high blood pressure, such as having a stroke. 
See võib vähendada kõrge vererõhuga seotud riske, nagu insult.
Enviage is used to treat essential hypertension (high blood pressure). 
Enviaget kasutatakse essentsiaalse hüpertensiooni (kõrge vererõhu) raviks.
Enviage also reduced blood pressure in patients with diabetes and patients who were overweight. 
Enviage vähendas vererõhku ka diabeediga või ülekaalulistel patsientidel.
What benefit has Enviage shown during the studies? 
Milles seisneb uuringute põhjal Enviage kasulikkus?
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ENVIAGE EPAR summary for the public 
EUROOPA AVALIK HINDAMISARUANNE ENVIAGE Kokkuvõte üldsusele
The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Enviage are greater than its risks for the treatment of essential hypertension. 
Inimravimite komitee otsustas, et Enviage kasulikkus essentsiaalse hüpertensiooni ravis on suurem kui ravimiga kaasnevad riskid.
The blood pressure was measured in ‘millimetres of mercury' (mmHg). 
Vererõhku mõõdeti millimeetrites elavhõbedasammast (mm Hg).
What is the risk associated with Enviage? 
Mis riskid Enviagega kaasnevad?
The most common side effect with Enviage (seen in between 1 and 10 patients in 100) is diarrhoea. 
Enviage kõige sagedam kõrvalnäht (esinenud ühel kuni kümnel patsiendil sajast) on kõhulahtisus.
What is Enviage? 
Mis on Enviage?
Enviage is a medicine that contains the active substance aliskiren. 
Enviage on ravim, mis sisaldab toimeainena aliskireeni.
The studies lasted between six and 52 weeks and the main measure of effectiveness was the change in blood pressure during either the resting phase of the heartbeat (‘diastolic') or when the chambers of the heart were contracting (‘systolic'). 
Uuringute kestus oli 6-52 nädalat ja nende efektiivsust mõõdeti põhiliselt kas südame puhkefaasis või südame kokkutõmbumise ajal mõõdetud vererõhus (vastavalt diastoolne ja süstoolne vererõhk) toimunud muutuste järgi.
Why has Enviage been approved? 
Miks Enviage heaks kiideti?
By blocking the production of angiotensin I, levels of both angiotensin I and angiotensin II fall. 
Angiotensiin I blokeerimisel väheneb nii angiotensiin I kui ka angiotensiin II sisaldus veres.
The active substance in Enviage, aliskiren, is a renin inhibitor. 
Enviages toimeainena sisalduv aliskireen on reniini inhibiitor.
For the full list of all side effects reported with Enviage, see the Package Leaflet. 
Enviage kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
Enviage should not be used by people who may be hypersensitive (allergic) to aliskiren or any of the other ingredients. 
Enviaget ei tohi kasutada patsiendid, kes võivad olla aliskireeni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
Enviage, taken alone or in combination with other medicines, was also compared with other medicines for hypertension. 
Enviage kasutamist ainsa ravimina või koos teiste ravimitega võrreldi ka teiste kõrgvererõhuravimite kasutamisega.
Thirteen of the studies included patients with mild to moderate hypertension, and one included patients with severe hypertension. 
Kolmeteistkümnes uuringus osalesid kerge või mõõduka hüpertensiooniga ja ühes raske hüpertensiooniga patsiendid.
It must not be used in patients who have had angioedema (swelling under the skin) with aliskiren or in women who are more than three months pregnant. 
Ravimit ei tohi kasutada patsientidel, kellel on aliskireeni korral olnud angioödeem (nahaalune turse), ega rasedatel pärast esimest kolme raseduskuud.
In five of the studies, the effects of Enviage taken alone were compared with those of placebo (a dummy treatment). 
Viies uuringus võrreldi Enviage toimet selle kasutamisel ainsa ravimina platseebo (näiva ravimi) toimega.
Enviage must also not be taken with ciclosporin (a medicine that reduces the activity of the immune system), quinidine (used to correct irregular heartbeat) or verapamil (used to treat heart problems). 
Enviaget ei tohi manustada koos tsüklosporiiniga (immuunsüsteemi talitlust vähendav ravim), kinidiiniga (südame rütmihäirete ravim) ega verapamiiliga (südameravim).
Combination studies looked at Enviage used with an angiotensin converting enzyme inhibitor (ramipril), an angiotensin receptor blocker (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide). 
angiotensiini retseptorit blokeeriva ainega (valsartaan), beetablokaatoriga (atenolool), kaltsiumikanalit blokeeriva ainega (amlodipiin) ja diureetikumiga (hüdroklorotiasiid).
It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body. 
See blokeerib organismis aine angiotensiin I tekkes osaleva inimensüümi reniini toime.
The effects of Enviage were first tested in experimental models before being studied in humans. 
Enne inimuuringuid kontrolliti Enviage toimet muude katsetega.
It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Enviage. 
Seda manustatakse koos kerge einega, eelistatavalt iga päev samal kellaajal.
How is Enviage used? 
Kuidas Enviaget kasutatakse?
This was compared with a fall of 5.8 mmHg from 99.3 mmHg in the patients taking placebo. 
Sellega võrreldes vähenes platseebot kasutanud patsientide vererõhk (ravi algul keskmiselt 99,3 mm Hg) 5,8 mm Hg võrra.
What is Enviage used for? 
Milleks Enviaget kasutatakse?
The full EPAR for Enviage can be found here. 
Euroopa avaliku hindamisaruande täisteksti Enviage kohta leiate siit.
How has Enviage been studied? 
Kuidas Enviaget uuriti?
Enviage on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure. 
Enviage vähendas kasutamisel ainsa ravimina vererõhku efektiivsemini kui platseebo ja sama efektiivselt kui võrdlusravimid.
Other information about Enviage: 
Muu teave Enviage kohta
Larger falls were seen in patients aged 65 years or over and those taking higher doses of Enviage. 
Vähemalt 65-aastastel patsientidel ja Enviaget suuremates annustes kasutanud patsientidel vähenes vererõhk rohkem.
The dose of Enviage may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled. 
Patsientidel, kelle vererõhk ravile piisavalt ei allu, võib Enviage annust suurendada annuseni 300 mg üks kord päevas.
ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Lisateave on aadressil ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
EMA/249530/2015 EMEA/H/C/002772 
24. aprill 2015 EMA/372533/2015 EMEA/H/C/002772
The company provided data in experimental models from the scientific literature. 
Ettevõte esitas katsetulemused teaduskirjandusest.
The main measure of effectiveness was based on how long the patients lived without their cancer symptoms reappearing or until death. 
Efektiivsuse põhinäitaja oli aeg, kui kaua patsiendid elasid ilma vähisümptomite taastekketa, või aeg surmani.
What is Lympreva? 
Mis on Lympreva?
The CHMP also had some concerns regarding some aspects of the manufacture and quality control of the medicine. 
Samuti nägi inimravimite komitee põhjust ettevaatlikkuseks seoses ravimi tootmise ja kvaliteedikontrolli teatud aspektidega.
The CHMP considered that the way the main study was designed and carried out was inadequate to allow the Committee to establish the medicine's benefit. 
Inimravimite komitee leidis, et põhiuuringu ülesehitus ja korraldus ei olnud piisavalt asjakohane, et komitee saaks tõestada ravimi kasulikkust.
Therefore, at that point in time, the CHMP was of the opinion that the benefits of Lympreva did not outweigh its risks and recommended that it be refused marketing authorisation. 
Seetõttu oli inimravimite komitee sel ajal arvamusel, et Lympreva kasulikkus ei ole suurem kui sellega kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
The company also presented the results of one main study involving a total of 177 adults with follicular lymphoma who had responded to induction treatment with an established therapy known as PACE (prednisone, doxyrubicin, cyclophosphamide, and etoposide) and who had no sign of their disease. 
Lisaks esitas ettevõte tulemused ühest põhiuuringust, milles osales kokku 177 follikulaarse lümfoomiga täiskasvanut, kellel oli tekkinud ravivastus tõendatud toimega induktsioonravile PACE (prednisoon, doksürubitsiin, tsüklofosfamiid, etoposiid) ja kellel puudusid oma haiguse nähud.
The company that applied for authorisation is Biovest Europe Ltd. 
Müügiluba taotles Biovest Europe Ltd.
On 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Lympreva, intended for the treatment of patients with follicular non-Hodgkin's lymphoma. 
23. aprillil 2015 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda andmast müügiluba ravimile Lympreva, mida kavatseti kasutada follikulaarse mitte-Hodgkini lümfoomiga patsientide raviks.
It was expected to be used in combination with another medicine called granulocyte macrophage colony-stimulating factor (GM-CSF). 
Seda kavatseti kasutada kombinatsioonis teise ravimiga, mida nimetatakse granulotsüütide-makrofaagide kolooniat stimuleerivaks faktoriks (GM-CSF).
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom24 April 2015 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
Refusal of the marketing authorisation for Lympreva (dasiprotimut-T) 
Lympreva (dasiprotimut-T) müügiloa andmisest keeldumine
Lympreva is prepared individually for each patient from a sample of their own lymphoma cells. 
Lympreva valmistatakse iga patsiendi jaoks individuaalselt tema enda lümfoomirakkudest.
Refusal of the marketing authorisation for Lympreva (dasiprotimut-T) EMA/249530/2015 
Lympreva (dasiprotimut-T) müügiloa andmisest keeldumine EMA/372533/2015
Patients were given either Lympreva together with GM-CSF, or haemocyanin with GM-CSF. 
Patsientidele manustati kas Lymprevat koos GM-CSF-iga või hemotsüaniini koos GM-CSF-iga.
In addition, the effectiveness of Lympreva following induction treatment with the current standard of care (the so-called ‘anti-CD20' therapies) has not been demonstrated. 
Lisaks ei tõendatud Lympreva efektiivsust standardse induktsioonravi (CD20-vastase ravi) järel.
The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with Lympreva. 
Ettevõte teatas inimravimite komiteele, et Lympreva kliinilisi uuringuid ega eriloaga kasutamise programme praegu ei toimu.
Lympreva is a type of ‘cancer immunotherapy' medicine, a medicine designed to stimulate the patient's immune system (the body's natural defences) so that it attacks and kills the cancer cells. 
Lympreva on vähi immunoteraapia ravim, mille eesmärk on stimuleerida patsiendi immuunsüsteemi (organismi looduslikku kaitsemehhanismi), et see ründaks ja hävitaks vähirakke.
The medicine is made up of a protein found in the patient's lymphoma cells, attached to a molecule called haemocyanin, which helps to activate the immune system against the lymphoma cells. 
Ravim koosneb patsiendi lümfoomirakkudes esinevast valgust, mis on kinnitunud hemotsüaniini molekulile, mis aitab aktiveerida immuunsüsteemi lümfoomirakkudega võitlemiseks.
How is Lympreva expected to work? 
Milline on Lympreva eeldatav toime?
Lympreva was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 28 August 2006, for the treatment of follicular lymphoma. 
Lympreva nimetati 28. augustil 2006 follikulaarse lümfoomi harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
Lympreva was expected to be used to treat adults with follicular non-Hodgkin's lymphoma, a cancer of a type of white blood cells called ‘B cells'. 
Lymprevat kavatseti kasutada täiskasvanute raviks, kellel on follikulaarne mitte-Hodgkini lümfoom, mis on teatud leukotsüütide B-rakkude vähk.
When injected into the patient's body, these lymphoma-specific proteins are expected to stimulate certain components of the immune system to attack and kill the lymphoma cells. 
Patsiendi organismi süstituna stimuleerivad lümfoomile toimivad valgud eeldatavasti immuunsüsteemi teatud komponente, et need ründaksid ja hävitaksid lümfoomirakke.
Lympreva is a medicine that contains the active substance dasiprotimut-T. 
Lympreva on ravim, mis sisaldab toimeainena dasiprotimut-T-d. Seda kavatseti turustada subkutaanse süstesuspensioonina.
What was Lympreva expected to be used for? 
Milleks kavatseti Lymprevat kasutada?
Lympreva was expected to be given to patients whose signs of disease had disappeared following an ‘induction' treatment, to maintain the complete disappearance of symptoms of cancer. 
Lymprevat kavatseti manustada patsientidele, kelle haigusnähud olid pärast induktsioonravi taandunud, et vähisümptomid ei tekiks uuesti.
Copalia HCT with food, drink and alcohol 
Copalia HCT koos toidu, joogi ja alkoholiga
Do not take Copalia HCT if you are more than 3 months pregnant. 
Ärge võtke Copalia HCT'd - kui te olete rase üle 3 kuu.
You should never take Copalia HCT again. 
Te ei tohiks enam kunagi Copalia HCT'd võtta.
Children and adolescents The use of Copalia HCT in children and adolescents under 18 years of age is not recommended. 
Lapsed ja noorukid Copalia HCT kasutamine lastel ja alla 18-aastastel noorukitel ei ole soovitatav.
(It is also recommended to avoid Copalia HCT in early pregnancy - see Pregnancy section.) 
(Samuti on soovitatav vältida Copalia HCT võtmist enne rasedustvt lõik Rasedus.)
Your doctor will normally advise you to stop taking Copalia HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Copalia HCT. 
Tavaliselt soovitab arst teil lõpetada Copalia HCT kasutamine enne rasestumist või niipea, kui te saate teada, et te olete rase ja soovitab teil kasutada Copalia HCT asemel mõnda muud ravimit.
See also information under the heading “Do not take Copalia HCT”. 
Vt ka teavet lõigus „Ärge võtke Copalia HCT'd“.
The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Copalia HCT. 
Täielik vererõhku langetav toime saavutati 2 nädalat pärast Copalia HCT maksimaalse annuse kasutamist.
However, it is important to take into account that Copalia HCT may increase the hypotensive effect of other antihypertensive agents. 
Samas on tähtis arvestada sellega, et Copalia HCT võib suurendada teiste antihüpertensiivsete ravimite hüpotensiivset toimet.
These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking Copalia HCT. 
Need võivad olla silmasisese rõhu tõusu sümptomiteks ning tekkida tundide kuni nädala jooksul pärast Copalia HCT võtmist.